Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: Due to a heightened risk of progressive multifocal leukoencephalopathy (PML) with increased natalizumab exposure, some physicians interrupt treatment of patients with multiple sclerosis (MS) despite a lack of data regarding the safety of treatment interruption, the rate and severity of MS disease activity return after treatment interruption, or alternative treatment strategies.
Objectives: To determine the effects of natalizumab treatment interruption on clinical and MRI measures of disease activity in relapsing patients with MS.
Methods: Clinical relapses and gadolinium-enhanced (Gd+) lesions were analyzed over an 8-month period in patients from the AFFIRM, SENTINEL, and GLANCE studies of natalizumab, and their respective safety extension studies, following the voluntary suspension of natalizumab dosing that occurred in February 2005.
Results: Relapses were analyzed in 1,866 patients, and Gd+ lesions were analyzed in 341 patients. Annualized relapse rates and Gd+ lesions both increased shortly after natalizumab interruption and peaked between 4 and 7 months. A consistent return of disease activity was observed regardless of overall natalizumab exposure, whether or not patients received alternative MS therapies, and in patients with highly active MS disease. A rebound of relapse or Gd+ lesion activity, beyond placebo-treated levels from the clinical studies, was not observed in any of the analyses conducted.
Conclusions: Following interruption of natalizumab treatment, MS disease activity returned in a pattern that was consistent with known pharmacokinetic and pharmacodynamic properties of natalizumab, and did not show evidence of rebound.
Footnotes
Study funding: Supported in part by Biogen Idec and Elan Corporation.
Editorial, page 1854
Supplemental data at www.neurology.org
-
- ARR
- annualized relapse rates
- CI
- confidence interval
- EDSS
- Expanded Disability Status Scale
- Gd+
- gadolinium-enhanced
- MS
- multiple sclerosis
- PML
- progressive multifocal leukoencephalopathy
- Received August 7, 2010.
- Accepted December 27, 2010.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Reply to the authors
- Paul W O'Connor, Neurologist, St Michaels Hospital, University of Torontooconnorp@smh.ca
Submitted August 26, 2011 - Evidence for Rebound During Natalizumab Treatment Interruption
- Kottil W. Rammohan, Instructor of Neurology, University of Miamimortega2@med.miami.edu
- Milissa R. Ortega, Silvia R. Delgado, Leticia Tornes
Submitted August 23, 2011
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
MS disease activity in RESTOREA randomized 24-week natalizumab treatment interruption studyRobert J. Fox, Bruce A.C. Cree, Jerome De Sèze et al.Neurology, March 28, 2014 -
Article
Risk of relapse after natalizumab withdrawalResults from the French TYSEDMUS cohortCaroline Papeix, Sandra Vukusic, Romain Casey et al.Neurology: Neuroimmunology & Neuroinflammation, October 28, 2016 -
Article
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patientsTatiana Plavina, Kumar Kandadi Muralidharan, Geoffrey Kuesters et al.Neurology, September 15, 2017 -
Research
Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practiceCarrie M. Hersh, Haleigh Harris, Devon Conway et al.Neurology: Clinical Practice, February 12, 2020